US Joint Pain Injections Market Size, Share & Growth Analysis By Product Type (Corticosteroid Injections, Hyaluronic Acid Injections, Platelet-Rich Plasma (PRP) Injections, Biologic & Regenerative Therapies), By Joint Type (Knee, Hip, Shoulder, Hand & Wrist, Ankle, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End-User (Hospitals, Orthopedic Clinics, Ambulatory Surgical Centers, Sports Medicine Centers), Industry Trends, Competitive Landscape, Regional Outlook & Forecast 2025–2034

Key Player Analysis

Zimmer Biomet: Zimmer Biomet holds a leadership position in the joint pain injections market through its strong presence in orthopedics and sports medicine. The company benefits from deep relationships with hospitals and ambulatory surgery centers, which drive bundled adoption of injectable therapies alongside implants and surgical tools. Its injectable portfolio supports pain management pathways for knee and hip conditions, which together account for more than 55 percent of global injection demand in 2025. Orthopedic-related products represent over 45 percent of Zimmer Biomet’s total revenue, reinforcing its influence on clinical protocols.

Strategically, Zimmer Biomet continues to expand procedure-based solutions rather than standalone products. It invests heavily in clinical data, surgeon training, and digital workflow integration to strengthen standard-of-care positioning. Geographic strength in North America and Western Europe provides pricing stability, while expansion across Asia Pacific supports mid-single-digit volume growth. The company differentiates through scale, surgeon loyalty, and integration across the full joint care continuum.

Sanofi: Sanofi operates as a major challenger in joint pain injections, supported by its global pharmaceutical footprint and established pain and inflammation franchise. The company maintains a strong presence in corticosteroid and anti-inflammatory injectables, which continue to account for more than 30 percent of total market revenue in 2025. Sanofi’s reach across public and private healthcare systems positions it well in cost-sensitive markets where reimbursement dictates therapy choice.

The company prioritizes lifecycle management and geographic expansion over rapid portfolio shifts. Ongoing investment in manufacturing efficiency and regulatory alignment supports consistent supply across Europe, Latin America, and parts of Asia. Sanofi differentiates through pricing discipline, distribution scale, and strong payer access. This strategy allows it to defend share despite rising competition from biologic and autologous therapies.

Pacira BioSciences Inc.: Pacira BioSciences positions itself as an innovator within non-opioid pain management and localized injection therapies. Its focus on extended-release formulations addresses demand for longer-lasting pain control in orthopedic and musculoskeletal procedures. In 2025, the company derives more than 60 percent of revenue from injectable pain solutions used in surgical and post-procedural settings, with joint-related applications representing a growing share.

Pacira invests heavily in R&D and clinical trials to expand labeled indications and strengthen physician adoption. Partnerships with hospital systems and outpatient centers support procedure-driven growth, particularly in the United States. The company differentiates through formulation science, duration of effect, and alignment with opioid-reduction policies. This positioning supports above-market revenue growth and strengthens its role in advanced pain management pathways.

Market Key Players

• Bioventus
• Dr. Reddy’s Laboratories Ltd.
• SEIKAGAKU CORPORATION
• Pacira BioSciences Inc.
• Ferring B.V.
• Zimmer Biomet
• Teva Pharmaceutical Industries Ltd.
• Anika Therapeutics Inc.
• Sanofi

Driver:

Aging Population Accelerating Injection Demand

As of 2025, population aging acts as the primary demand engine for joint pain injections. Adults aged 60 and above now represent more than 15 percent of the global population, and osteoarthritis prevalence exceeds 30 percent within this cohort. You see direct impact on procedure volumes, particularly in knee and hip injections, as patients delay or avoid surgical intervention. Joint pain injections offer rapid symptom control and functional improvement, which aligns with clinical guidelines favoring conservative care before surgery.

Clinical Integration Supporting Sustainable CAGR Growth

Healthcare systems increasingly integrate corticosteroid and hyaluronic acid injections into standard pain pathways. Adoption rates in orthopedic and rheumatology clinics exceed 65 percent for eligible patients. This clinical normalization supports stable demand growth and underpins a market CAGR close to 9 percent through 2032. For manufacturers and investors, aging demographics create predictable volume expansion and long product life cycles.

Restraint:

High Treatment Costs and Reimbursement Gaps

Treatment affordability remains a structural constraint in 2025. Average per-injection costs range from 300 to 1,200 USD depending on formulation and geography. Advanced biologic options such as platelet rich plasma often exceed 1,500 USD per cycle. You face uneven reimbursement coverage, especially outside North America and Western Europe, where public payers restrict usage or cap annual volumes.

Margin Pressure in Cost-Sensitive Markets

Out-of-pocket exposure reduces patient uptake by an estimated 20 to 25 percent in cost-sensitive markets. This pressure slows penetration of premium products and limits repeat treatment frequency. For suppliers, pricing resistance compresses margins and shifts growth reliance toward private-pay segments and high-income regions.

Opportunity:

Expansion of Image-Guided Injection Technologies

Advances in injection delivery technology create a clear expansion path beyond 2025. Image-guided systems using ultrasound or fluoroscopy now support more than 40 percent of hospital-based joint injections, up from roughly 25 percent five years ago. You gain higher placement accuracy, fewer repeat procedures, and improved patient outcomes, which strengthens provider preference.

Premium Positioning Through Integrated Solutions

This shift supports premium pricing and drives equipment and consumables revenue alongside injectables. The image-guided segment is projected to grow at over 10 percent annually through 2033. Companies investing in integrated kits and training programs stand to capture higher share within orthopedic and sports medicine practices.

Trend:

Growing Preference for Minimally Invasive Therapies

Patient and provider preference continues to move toward minimally invasive care. In 2025, more than 70 percent of patients with moderate joint pain choose injection-based therapy before considering surgery. You benefit from shorter recovery times, lower complication rates, and reduced hospital stays, which align with payer cost-control priorities.

Technological Advancements Enhancing Treatment Confidence

Technology progress reinforces this shift. Improved imaging, refined needle designs, and better formulation stability increase treatment confidence. As outcomes approach those of early surgical intervention for selected patients, minimally invasive joint injections strengthen their role as a first-line and repeatable solution across multiple joint indications.

Recent Developments

Dec 2024 – Taiwan Bio Therapeutics: The company signed a cooperation agreement with Singapore-based Senectus that set an option for exclusive Asia Pacific rights to develop and commercialize Chondrochymal, a cell therapy positioned for knee osteoarthritis injection-led care pathways.

Feb 2025 – Contura Orthopedics: Contura expanded Arthrosamid (iPAAG hydrogel) into Canada following Health Canada approval, moving the product closer to broader North American access for non-surgical knee osteoarthritis management.

Apr 2025 – Sun Pharma and Moebius Medical: The companies announced dual publications and congress data for MM-II, a single-injection, non-opioid knee osteoarthritis therapy supported by a Phase 2b study enrolling 397 patients across the US, Europe, and Asia, with reported pain relief through 26 weeks. The update strengthens late-stage credibility in a segment where estimated: 6.5% CAGR, symptomatic knee osteoarthritis injectables, 2025-2033.

Jul 2025 – Johnson & Johnson MedTech and Pacira BioSciences: Johnson & Johnson MedTech signed a strategic co-promotion agreement with Pacira to expand its Early Intervention portfolio with ZILRETTA, an extended-release intra-articular corticosteroid for knee osteoarthritis pain.

Sep 2025 – Contura Orthopedics: Contura launched a clinician-facing personalized video rehabilitation tool to complement Arthrosamid care pathways for knee osteoarthritis patients.